Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
IMPROVE 研究的最终结果:一项随机、对照、开放标签、双臂、交叉 IV 期研究,旨在确定晚期 HR 阳性、HER2 阴性乳腺癌患者对依维莫司联合依西美坦或卡培他滨联合贝伐单抗的偏好。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-020-06747-y
Decker, Thomas; Söling, Ulrike; Hahn, Antje; Maintz, Christoph; Kurbacher, Christian Martin; Vehling-Kaiser, Ursula; Sent, Dagmar; Klare, Peter; Hagen, Volker; Chiabudini, Marco; Falkenstein, Julia; Indorf, Martin; Runkel, Eva; Potthoff, Karin